1 of 1
Story summary
- About 12% of Americans use Wegovy and Zepbound.
- Up to 25% of users may be nonresponders, losing less than 5% of body weight.
- Factors influencing effectiveness include biological pathways, genetics, and individual traits.
- Some individuals have a hungry brain phenotype or a hungry gut phenotype that alter fullness signals.
- Genetic variations in the neurobeachin gene may affect drug response.
